[1] KRIS M G,GASPARL E,CHAFT J E,et al.Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA completely resected non-small-cell lung cancers:American society of clinical oncology/cancer care ontario clinical practice guideline update[J].J Clin Oncol,2017,35(25):2960-2974.
[2] MASTERS G A,TEMIN S,AZZOLI C G,et al,Systemic therapy for stage Ⅳ non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2015,33(30):3488-3515.
[3] 于舒飞,王燕.甲磺酸阿帕替尼治疗晚期非小细胞肺癌疗效分析[J].癌症进展,2012(6):605-611.
[4] 毕金玲,刘海源,黄勇.阿帕替尼单药治疗进展期非小细胞肺癌疗效观察[J].临床肺科杂志,2017(8):1474-1476.
[5] 王琳,冯久桓,秦叔逵.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017(4):345-356.
[6] SUN J M,AHN M J, PARK M J,et al.Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors[J].Lung Cancer,2010,69(1):105-109.
[7] LAKSHMAN A,MODI M,PRAKASH G,et al.Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction[J].Clin Lymphoma Myelom,2017,17(8):513-519.
[8] 范少泷,邹玉环,房芳,等.甲磺酸阿帕替尼治疗驱动基因未明的晚期非小细胞肺癌的观察性研究[J].中国医药导刊,2017,19(11):1150-1154.
[9] BESSE B.2nd ESMO consensus conference on lung cancer:non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease[J].Ann Oncol,2014,25(8):1475-1484.
[10] DING L,LI Q J,YOU K Y,et al.The use of apatinib in treating nonsmall-cell lung cancer:case report and review of literature[J].Medicine,2016,95(20):e3598.
[11] LANGER C J,MOK T,POSTMUS P E.Targeted agents in the third-/fourth-line treatment of patients with advanced (stage Ⅲ/Ⅳ) non-small cell lung cancer (NSCLC)[J].Cancer Treat Rev,2013,39(3):252-260.
[12] PENG S,ZHANG Y,PENG H,et al.Intracellular autocrine VEGF signaling promotes EBDC cell proliferation,which can be inhibited by apatinib[J].Cancer Lett,2016,373(2):193-202.
[13] LIN C,WANG S S,XIE W W.et al.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J].Oncotarget,2016,7(37):59236-59244.
[14] LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
[15] ROVIELLO G,PLOLOM K,ROVIELLO F,et al.Targeting VEGFR-2 in metastatic gastric cancer:results from a literature-based meta-analysis[J].Cancer Invest,2017,35(3):187-194.
[16] EMIL T V,HAJ M N,et al.Second-and third-line systemic therapy in patients with advanced esophagogastric cancer:a systematic review of the literature[J].CancerMetast Rev,2016,35(3):439-456.
[17] HU T,LIU C,LI Q,et al.Apatinib+CPT-11+S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer:case report and literature review[J].Medicine,2018,97(15):349-353.
[18] SCOTT A J,MESSERSMITH W A,JIMENO A.Apatinib:a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J].Drugs Today,2015,51(4):223-232.
[19] HU X,ZHANG J,XU B,et al.Multicenter phase Ⅱ study of apatinib,a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].breast,2014,135(8):1961-1969.
[20] ZHANG L,SHI M Q,HUANG C,et al.A phase Ⅱ,multicenter,placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens[J].J Clin Oncol,2012,30(S15):7548.
[21] LI J,QIN S,XU J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225. |